A possible increased risk of metamizole-associated neutropenia among COVID-19 patients.
Metamizole is commonly used as analgesic and antipyretic drug. The use of metamizole is prohibited in several countries due to its rare side effect of neutropenia and even agranulocytosis. Among the many symptoms of COVID-19, fever and diffuse pain predominant and therefore it can be assumed that metamizole may be widely used in the current epidemic period. So far, there have been no reports on the safety of metamizole in COVID-19 patients. We describe a series of 3 patients who developed severe neutropenia under metamizole treatment, raising a concern of a possible increased risk of this side effect among COVID-19 patients.
['Lerman|Tsahi T|TT|0000-0002-2491-9930', 'Sagi|Moshe|M|', 'Shafir|Yair|Y|', 'Sheena|Liron|L|', 'Cohen|Eytan|E|', 'Goldberg|Elad|E|', 'Krause|Ilan|I|']
D000894:Anti-Inflammatory Agents, Non-Steroidal D000086382:COVID-19 D004177:Dipyrone D006801:Humans D009503:Neutropenia D000086402:SARS-CoV-2
neutropenia COVID-19 metamizole agranulocytosis SARS-CoV-2 adverse drug reaction dipyrone